HMG-CoA reductase inhibitor extended release formulation
US8679534B2 · kind B2 · utility
0Cited by
87References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 16, 2006 |
| Grant date | Mar 25, 2014 |
| Priority date | — |
| Expiry date | May 31, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at about 10 to about 32 hours after oral administration on a once-a-day basis to human patients. The dosage form provides a therapeutically effective reduction in serum cholesterol levels. Methods of reducing serum cholesterol levels in humans are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.